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Despite improving success rate of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) 
lesions, the clinical benefit of recanalization of CTO is still a matter of debates. The purpose of this study is to 
elucidate the impact of successful PCI for CTO on cardiovascular outcome in a large Japanese observational 
database of patients who underwent first coronary revascularization. Among 13087 patients who underwent PCI 
in the CREDO-Kyoto registry Cohort-2, 1524 patients received PCI for CTO. Clinical outcomes were compared 
between 1192 patients with successful CTO-PCI and 332 patients with failed CTO-PCI. In-hospital death tended 
to occur less frequently in the successful CTO-PCI group than in the failed CTO-PCI group (1.4% vs. 3.0%, 
P=0.053). Through 3-year follow-up, the cumulative incidence of all-cause death was not significantly different 
between the successful and failed CTO-PCI groups (9.0% vs. 13.1%, p=0.18), while the cumulative incidence of 
cardiac death was significantly lower in the successful CTO-PCI group than in the failed CTO-PCI group (4.5% 
vs. 8.4%, P=0.03). However, after adjusting confounders, successful PCI for CTO was not associated with lower 
risk for all-cause death (Hazard ratio [HR]: 0.93, 95% confidence interval [CI]: 0.64-1.37, P=0.69) nor for cardiac 
death (HR: 0.71, 95% CI: 0.44-1.16, P=0.16). The cumulative incidence of coronary artery bypass grafting 
(CABG) was remarkably lower in patients with successful PCI compared to those with failed PCI (1.8% vs. 
19.6%, P<0.0001). In conclusion, successful PCI for CTO as compared with failed PCI was not associated with 
lower risk for 3-year mortality.  




Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) has dramatically changed in 
recent years. The improvement of devices such as the guidewires, microcatheters, as well as low-profile balloon 
catheters and refinement of operator techniques such as parallel wire technique and retrograde approach have 
contributed to the improved success rate for CTO-PCI, although the penetration rates of parallel wire technique and 
retrograde approach might be different between Japan and outside Japan.1 Furthermore, introduction of drug-eluting 
stent (DES) has significantly reduced the restenosis and reocclusion rates in the CTO lesions.2-3 Successful 
CTO-PCI has been reported to be associated with less subsequent coronary artery bypass grafting (CABG), 
improvement of left ventricular function and relief of symptoms.4-6 There are several reports that successful 
CTO-PCI improved the long-term survival outcomes after revascularization.7-8  Recently, Mehran and Jones also 
reported successful PCI for CTO was independently associated with lower cardiac morality.9-10 However, many 
previous studies were associated with relatively low procedural success rates. Procedural success rate itself might 
have significant influence in analyzing the effect of successful CTO-PCI on survival outcome. Survival outcome 
after CTO-PCI should also be investigated in a population with relatively high procedural success rates. Therefore, 
we analyzed the impact of successful PCI for CTO on cardiovascular outcomes in a large Japanese observational 
database of patients who underwent first coronary revascularization. 
Methods 
The CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome study in Kyoto) percutaneous 
coronary intervention (PCI)/coronary artery bypass grafting (CABG) registry cohort-2 is a multi-center registry 
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enrolling consecutive patients undergoing first coronary revascularization procedures among 26 centers in Japan 
between January 2005 and December 2007 (Supplementary Appendix A). The relevant review boards or ethics 
committees in all participating centers approved the research protocol. Because of retrospective enrollment, written 
informed consents from the patients were waived; however, we excluded those patients who refused participation in 
the study when contacted for follow-up. This strategy is concordant with the guidelines for epidemiological studies 
issued by the Ministry of Health, Labor and Welfare of Japan. 
The design and patient enrollment of the CREDO-Kyoto PCI/CABG registry cohort-2 has been described 
previously.11 Among a total of 15263 patients, 13087 patients underwent PCI as their first coronary 
revascularization procedure during the 3 years of enrollment period. Among 2491 patients (19%) with at least 1 
CTO lesion, 1524 patients underwent attempt of PCI for CTO lesions. PCI for at least one CTO lesion was 
successful in 1192 patients (successful CTO-PCI group), while PCI for CTO lesions was unsuccessful in 332 
patients (failed CTO-PCI group) (78% initial patient success rate for CTO) (Figure 1). The number of cases and 
initial success rate of CTO-PCI in each participating center were illustrated in Supplemental Figure 1. In the 
successful PCI group, 1230 lesions out of 1245 CTO lesions in 1192 patients were successfully treated (1154 
patients had 1 treated CTO lesion and 38 patients had 2 treated CTO lesions). A total of 2032 stents were used in 
the successful CTO-PCI group; 1589 were drug-eluting stents (78%) and 443 were bare-metal stents (22%). In the 
failed PCI group, no CTO lesion among 339 CTO lesions in 332 patients was successfully treated, while 262 
non-CTO lesions were successfully treated in 177 patients. In the current pre-specified substudy of the 
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CREDO-Kyoto PCI/CABG registry cohort-2, we compared 3-year clinical outcome between the successful and 
failed CTO-PCI groups.   
 Definitions of baseline clinical characteristics were described previously.11 CTO was defined as 
complete obstruction of the vessel with Thrombolysis In Myocardial Infarction (TIMI) flow of 0 or 1 with an 
estimated duration of the occlusion >1 month or presence of collateral flow. The duration of occlusion was judged 
by the investigators in each participating center on the basis of the interval from the last episode of myocardial 
infarction (MI) in the target vessel territory, the previous coronary angiography, or changes in electrocardiographic 
findings. Procedural success was defined as a final diameter stenosis of <50% and a TIMI flow of 2 or 3.  
All-cause death was regarded as the primary outcome measure in the current analysis. Cardiac death, MI, 
stroke, stent thrombosis (ST), CABG and any coronary revascularization were also assessed as endpoints. Death 
was regarded as cardiac in origin unless an obvious non-cardiac cause could be identified. Any death during the 
index hospitalization was regarded as cardiac death. MI was defined according to the definition in the Arterial 
Revascularization Therapy Study.12 Within 1 week of the index procedure, only Q-wave MI was adjudicated as MI. 
Stroke was defined as ischemic or hemorrhagic stroke either occurring during the index hospitalization or requiring 
hospitalization with symptoms lasting >24 hours. ST was defined according to the Academic Research Consortium 
(ARC) definition.13 ARC definite ST was used as the end point for ST in this study. The recommend antiplatelet 
regimen was aspirin (≥81 mg daily) indefinitely and thienopyridine (200 mg ticlopidine or 75 mg clopidogrel daily) 
for at least 3 months. Duration of antiplatelet therapy was left to the discretion of each attending physician.  
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Demographic, angiographic, and procedural data were collected from hospital charts or databases 
according to the pre-specified definitions by the experienced clinical research coordinators in the independent 
clinical research organization (Research Institute for Production Development, Kyoto, Japan) (Supplementary 
Appendix B). Follow-up data were collected also by the experienced clinical research coordinators from hospital 
charts or by contacting patients, or referring physicians. Death, MI, stroke and ST were adjudicated against original 
source documents by a clinical event committee (Supplementary Appendix C). Median follow-up duration was 934 
(inter-quartile range [IQR]: 669-1243) days. 
Categorical variables were compared with the chi-square test. Continuous variables were expressed as 
mean value ± standard deviation or median and IQR. Continuous variables were compared using the Student’s t-test 
or Wilcoxon rank sum test based on their distributions. Cumulative incidence was estimated by the Kaplan-Meier 
method and differences were assessed with the log-rank test. We used Cox proportional hazard models to estimate 
the risk of the successful CTO-PCI group relative to the failed CTO-PCI group adjusting for the differences in 
patient characteristics and procedural factors as well as medications. In consistent with our previous reports, we 
selected 34 clinically relevant factors shown in Table 1 as potential independent risk-adjusting variables.11,14 
Independent correlates for all-cause death were identified by a backward elimination procedure (Supplemental 
Table 1). The final model incorporated the successful CTO-PCI together with 8 variables remaining after the 
backward procedure. Adjusted analysis for the other endpoints was performed by using the same 8 risk-adjusting 
variables as used in the analysis for all-cause death. The continuous variables were dichotomized by clinically 
meaningful reference values or median values. The effect of the successful CTO-PCI (the successful CTO-PCI 
  
7 
group compared to the failed CTO-PCI group) was expressed as hazard ratios (HR) and their 95% confidence 
intervals (CI). Post-hoc subgroup analysis was also conducted for an exploratory purpose in several clinically 
relevant subgroups. Statistical analyses were conducted by two physicians (Yamamoto E and Natsuaki M) and by a 
statistician (Morimoto T) with the use of JMP 10.0 (SAS Institute Inc, Cary, NC) and SAS 9.2 (SAS Institute Inc, 
Cary, NC) softwares. All the statistical analyses were two-tailed. P values <0.05 were considered statistically 
significant. 
Results 
        At baseline, acute myocardial infarction, shock at presentation, multivessel disease, moderate to severe 
mitral regurgitation and dialysis were more prevalent in the failed CTO-PCI group than in the successful CTO-PCI 
group, while prior MI was more common in the successful CTO-PCI group. Regarding lesion and procedural 
characteristics, right coronary artery was more frequently targeted in the failed CTO-PCI group than in the 
successful PCI group. Aspirin and thienopyridine were more frequently used in the successful CTO-PCI group than 
in the failed CTO-PCI group, while nitrates were more often used in the failed CTO-PCI group (Table 1). 
Regarding the procedural complications, coronary perforation was significantly more frequent in the failed 
CTO-PCI group than in the successful CTO-PCI group. However, there was no significant difference in the 
incidences of coronary dissection, cardiac tamponade and pericardial drainage between the 2 groups (Table 2). 
Regarding the in-hospital adverse events, incidence of death and MI tended to be lower in the successful CTO-PCI 
group. However, there was no significant difference in the incidence of stroke between the 2 groups (Table 2). 




(IQR: 635-1235) days in the failed PCI group. The median duration of dual anti-platelet therapy (DAPT) was 
significantly different between the successful and failed PCI groups (475 [IQR: 91-874] days vs. 35 [IQR: 1-543] 
days, P<0.0001) (Supplemental Figure 2). Through 3-year follow-up, the cumulative incidence of all-cause death 
was not significantly different between the successful and failed CTO-PCI groups, while the cumulative incidence 
of cardiac death was significantly lower in the successful CTO-PCI group than in the failed CTO-PCI group (Table 
3, and Figure 2). After adjusting confounders, however, the risks of successful PCI relative to failed PCI for both 
all-cause death and cardiac death were not significant (Table 3). There was no significant difference in the 
incidences of MI, stroke and definite ST between the 2 groups (Table 3, and Figure 3). The adjusted risks of 
successful PCI relative to failed PCI for MI, stroke and definite ST were also not significant (Table 3). Cumulative 
incidence of CABG was remarkably lower in the successful PCI group than in the failed PCI group. The 
cumulative incidence of any coronary revascularization was also lower in the successful PCI group than in the 
failed PCI group (Figure 3). Even after adjusting confounders, the lower risk of successful PCI relative to failed 
PCI for CABG and any coronary revascularization remained significant (Table 3). 
In the post-hoc subgroup analysis, successful PCI was not associated with lower risk for all-cause death in 
any of the subgroups evaluated. However, successful PCI was associated with lower risk for cardiac death in 
several subgroups including patients with treated CTO lesion located in left anterior descending artery, patients 
with single vessel disease, patients without history of heart failure, and patients without diabetic mellitus (Table 4).   
Discussion 




PCI for CTO was not associated with lower risk for 3-year mortality; (2) However, successful PCI for CTO was 
associated with significantly lower risk for subsequent CABG. CTO-PCI was one of the most challenging fields in 
the interventional cardiology in the past decade. In the early 2000s, the success rate of CTO-PCI was 60%-70%.9,15 
Recently, the reported success rate of CTO-PCI has reached >80% owing to the development of devices such as 
tapered wires or micro-catheters as well as advances in operators’ techniques such as parallel wire technique and 
retrograde approach.16-19 In consistent to these reports, initial patient success rate of CTO-PCI was 78% in this 
study. Successful CTO-PCI is reported to be associated with less subsequent CABG, improvement in left 
ventricular function and relief of symptoms, which are the main reasons for physicians to perform CTO-PCI.4-6 
However, the impact of successful PCI for CTO on long-term prognosis is still a matter of debates. 8,20-23 Most of 
previous studies evaluating the impact of successful CTO-PCI on long-term outcome adopted the methodology 
comparing the long-term mortality after successful CTO-PCI with that after failed CTO-PCI. Suero and Hoye 
reported successful revascularization of CTO were independent predictors of all-cause death.7,15 Recently, Mehran 
reported that successful PCI for CTO was an independent predictor of all-cause death and cardiac death.9  
In this study, successful PCI for CTO was not associated with lower risk for all-cause death and cardiac 
death. This result is not consistent to previous reports and there might be several reasons for this discrepancy. First, 
complications of CTO-PCI might have some influence on the mortality after PCI. Coronary perforation was 
significantly higher in the failed CTO-PCI group than in the successful CTO-PCI group in this study. However, 
there were no significant differences in the frequency of severe complications such as cardiac tamponade or 
pericardial drainage. In contrast, severe complications were more frequent in the failed PCI group than in the 
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successful PCI group in previous reports. Mehran et al. reported rate of coronary perforation and residual dissection 
was 7.4% and 9.4% respectively in failed group, and 1.7% and 4.3% in success group.9 Olivari reported that 2.3% 
of patients in the failed CTO-PCI group underwent emergent CABG (no emergent CABG in our study).4 
Additionally, some reports reported that the incidence of in-hospital MACE was significantly high in failed 
CTO-PCI group.7,15 Second, the difference in the rate of subsequent revascularization after the index PCI might be 
related to the difference in the outcome. Valenti reported that the incidence of CABG at 1 year was 9.1% in the 
failed PCI group, which was remarkably lower compared with current study (17.9%).23 Additionally, among 332 
patients in the failed CTO-PCI group, 167 patients underwent repeated revascularization procedures for CTO 
during 3 years and 113 patients got successful revascularization (PCI: 53 patients, CABG: 60 patients). Subsequent 
coronary revascularization in patients with failed CTO-PCI might heve attenuated the possible long-term mortality 
benefit of successful CTO-PCI. Third, the differences in background patient characteristics between the success and 
failed CTO-PCI groups should be taken in consideration. Fefer et al reported that only 10% of patients who have 
CTO lesions underwent CTO-PCI in Canadian multicenter chronic total occlusion registry.24 In contrast, 1524 
patients out of 2491 patients with CTO lesions (61%) underwent CTO-PCI in this study. Patients’ backgrounds in 
this study seemed to be worse compared to those reported in previous studies. Additionally, due to relatively high 
initial success rate, successful CTO-PCI group included many patients with complex clinical and procedural 
characteristics, who are deemed to have poor long-term prognosis. The success rates of CTO-PCI reported in 
previous studies suggesting better survival outcome after successful CTO-PCI were lower than the success rate in 
our study (Mehran: 68.5%, Jones: 69.6%, Aziz: 69.4%).9,10,25 It might be postulated that many complex patients 
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included in the successful CTO-PCI group in our study could be included in the failed CTO-PCI group in these 
previous reports, leading to worse survival outcome in the failed CTO-PCI group. Indeed, the failed CTO-PCI 
group in these previous reports included more patients with older age,23 lower left ventricular ejection fraction, and 
previous MI10 than the successful CTO-PCI group, while in the current study, there was no significant difference 
between the successful and failed CTO-PCI groups with regard to these factors.  
There is no randomized controlled trial comparing PCI plus medical therapy with medical therapy alone in 
patients with CTO. Given the discrepancy between the current and previous studies in terms of long-term mortality 
benefit of successful CTO-PCI, it is currently unclear whether successful CTO-PCI could improve long-term 
mortality. Recently, the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME-2) study 
demonstrated that in patients with stable coronary artery disease (CAD) and functionally significant stenosis, PCI 
guided by fractional flow reserve plus the best available medical therapy, as compared with the best available 
medical therapy alone, decreased the need for urgent revascularization.26 However, the benefit of avoiding the need 
for urgent revascularization could not be expected in stable CAD patients with CTO. A significant proportion of 
stable CAD patients with CTO are asymptomatic and therefore, we also could not expect symptomatic relief in this 
patient population. Furthermore, recent prospective randomized trials comparing PCI using DES with CABG in 
patients with complex multivessel CAD clearly demonstrated better long-term survival with less MI during 
follow-up with CABG.27-28 Therefore, most of the complex multivessel CAD patients with CTO should be referred 
to CABG surgery, although the above mentioned randomized controlled trials included relatively small number of 
patients with CTO (6-24%). According to these recent observations, the appropriate indications for CTO-PCI 
  
12 
seemed to be limited.  
In the exploratory subgroup analysis of this study, successful PCI was associated with lower risk for 
cardiac death in several subgroups. Safley also reported that successful PCI for CTO was a multivariable predictor 
for long-term survival in patients with treated LAD CTO lesion.29 Therefore, it is possible that successful CTO-PCI 
could be associated with improved survival outcome in some selected subgroups of patients. However, we should 
be very careful in interpreting the results of the subgroup analysis in the overall negative study.  
Prospective randomized trials comparing PCI plus medical therapy with medical therapy alone in patients 
with CTO, adequately powered for evaluating long-term mortality, are absolutely required to define the indication 
of PCI for CTO. Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total 
Occlusion (DECISION-CTO) trial is currently ongoing. 
 There are several limitations in this study. This is an observational study and the baseline patient 
characteristics were significantly different between the 2 groups. Despite statistical adjustment, it was not certain 
whether the mortality outcome was related to the successful CTO-PCI itself or was related to the presence of 
unmeasured confounders. Second, the current analysis was obviously underpowered in evaluating long-term 
mortality, although we enrolled relatively large number of patients with CTO as compared with previous studies. 
Third, there were no criteria to perform PCI for CTO lesions and the decision was left to each attending physician. 
Therefore, the conclusions of the current study could not be extrapolated to CTO-PCI in general. Fourth, patients 
with failed CTO-PCI are not equivalent to those patients with CTO who were managed with medical therapy alone. 




be different according to the centers or operators. Sixth, the low treatment rate of statins, beta blockers, angiotensin 
converting enzyme inhibitors and angiotensin II receptor blockers may have significant impact on the overall event 
rates at follow-up. Seventh, successful intervention of non-CTO lesions may lead to difficulty in detecting a 
difference between the 2 groups. Furthermore, high rate of subsequent coronary revascularization in patients with 
failed CTO-PCI might have attenuated the possible long-term mortality benefit of successful CTO-PCI in this study. 
Eighth, the duration of DAPT was different between the successful and failed PCI group, which might have 
influenced the long-term outcome. Finally, there was no information about the viability or ischemia in the 
myocardial territory subtended by the targeted lesions in this study. 
Acknowledgement 
We appreciate the collaboration of the co-investigators in the CREDO-Kyoto PCI/CABG Registry 






1. Rathore S, Matsuo H, Terashima M, Kinoshita Y, Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura Y, 
Katoh O, Suzuki T. Procedural and in-hospital outcomes after percutaneous coronary intervention for chronic 
total occlusions of coronary arteries 2002 to 2008: Impact of novel guidewire techniques. JACC Cardiovasc 
Interv 2009;2:489-497 
2. Colmenarez HJ, Escaned J, Fernandez C, Lobo L, Cano S, del Angel JG, Alfonso F, Jimenez P, Banuelos C, 
Gonzalo N, Garcia E, Hernandez R, Macaya C. Efficacy and safety of drug-eluting stents in chronic total 
coronary occlusion recanalization: A systematic review and meta-analysis. J Am Coll Cardiol 
2010;55:1854-1866 
3. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, Tanguay JF, Holper EM, 
Abbott JD, Lee JS, Smith C, Anderson WD, Kelsey SF, Kip KE. A comparison of bare-metal and drug-eluting 
stents for off-label indications. N Engl J Med 2008;358:342-352 
4. Olivari Z, Rubartelli P, Piscione F, Ettori F, Fontanelli A, Salemme L, Giachero C, Di Mario C, Gabrielli G, 
Spedicato L, Bedogni F. Immediate results and one-year clinical outcome after percutaneous coronary 
interventions in chronic total occlusions: Data from a multicenter, prospective, observational study 
(TOAST-GISE). J Am Coll Cardiol 2003;41:1672-1678 
5. Sirnes PA, Myreng Y, Molstad P, Bonarjee V, Golf S. Improvement in left ventricular ejection fraction and wall 
motion after successful recanalization of chronic coronary occlusions. Eur Heart J 1998;19:273-281 
6. Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the early health status benefits of successful 
chronic total occlusion recanalization: Results from the flowcardia's approach to chronic total occlusion 
  
15 
recanalization (FACTOR) trial. Circ Cardiovasc Qual Outcomes 2010;3:284-290 
7. Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi LV, Johnson WL, Rutherford BD. Procedural 
outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic 
total occlusion in native coronary arteries: A 20-year experience. J Am Coll Cardiol 2001;38:409-414 
8. Joyal D, Afilalo J, Rinfret S. Effectiveness of recanalization of chronic total occlusions: A systematic review 
and meta-analysis. Am Heart J 2010;160:179-187 
9. Mehran R, Claessen BE, Godino C, Dangas GD, Obunai K, Kanwal S, Carlino M, Henriques JP, Di Mario C, 
Kim YH, Park SJ, Stone GW, Leon MB, Moses JW, Colombo A. Long-term outcome of percutaneous coronary 
intervention for chronic total occlusions. JACC Cardiovasc Interv 2011;4:952-961 
10. Jones DA, Weerackody R, Rathod K, Behar J, Gallagher S, Knight CJ, Kapur A, Jain AK, Rothman MT, 
Thompson CA, Mathur A, Wragg A, Smith EJ. Successful recanalization of chronic total occlusions is 
associated with improved long-term survival. JACC Cardiovasc Interv 2012;5:380-388 
11. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Iwabuchi M, Shizuta S, Shiomi H, Tada T, Tazaki 
J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Miki S, Matsuda M, Takahashi M, Ishii K, Tanaka M, 
Aoyama T, Doi O, Hattori R, Tatami R, Suwa S, Takizawa A, Takatsu Y, Takahashi M, Kato H, Takeda T, Lee 
JD, Nohara R, Ogawa H, Tei C, Horie M, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T. 
Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice 
in Japan. Cardiovasc Interv and Ther 2011;26:234-245. 
12. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schonberger JP, Buller N, Bonser R, 
  
16 
Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary stenting versus 
bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization 
Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005;46:575-581. 
13. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical 
trials of drug-eluting stents N Engl J Med. 2007 Mar 8;356(10):1020-1029 
14. Natsuaki M, Nakagawa Y, Morimoto T, Ono K, Shizuta S, Furukawa Y, Kadota K, Iwabuchi M, Kato Y, Suwa 
S, Inada T, Doi O, Takizawa A, Nobuyoshi M, Kita T, Kimura T. Impact of statin therapy on late target lesion 
revascularization after sirolimus-eluting stent implantation (from the CREDO-Kyoto Registry Cohort-2). Am J 
Cardiol 2012;109:1387-1396 
15. Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total 
occlusions: The Thoraxcenter experience 1992-2002. Eur Heart J 2005;26:2630-2636 
16. Galassi AR, Tomasello SD, Reifart N, Werner GS, Sianos G, Bonnier H, Sievert H, Ehladad S, Bufe A, Shofer J, 
Gershlick A, Hildick-Smith D, Escaned J, Erglis A, Sheiban I, Thuesen L, Serra A, Christiansen E, Buettner A, 
Costanzo L, Barrano G, Di Mario C. In-hospital outcomes of percutaneous coronary intervention in patients 
with chronic total occlusion: Insights from the ERCTO (European Registry of Chronic Total Occlusion) 
registry. EuroIntervention 2011;7:472-479 
17. Morino Y, Kimura T, Hayashi Y, Muramatsu T, Ochiai M, Noguchi Y, Kato K, Shibata Y, Hiasa Y, Doi O, 
Yamashita T, Morimoto T, Abe M, Hinohara T, Mitsudo K. In-hospital outcomes of contemporary percutaneous 
coronary intervention in patients with chronic total occlusion insights from the j-CTO registry (multicenter 
  
17 
CTO registry in Japan). JACC Cardiovasc Interv 2010;3:143-151 
18. Mitsudo K, Yamashita T, Asakura Y, Muramatsu T, Doi O, Shibata Y, Morino Y. Recanalization strategy for 
chronic total occlusions with tapered and stiff-tip guidewire. The results of CTO new technique for standard 
procedure (conquest) trial. J Invasive Cardiol 2008;20:571-577 
19. Sianos G, Barlis P, Di Mario C, Papafaklis MI, Buttner J, Galassi AR, Schofer J, Werner G, Lefevre T, Louvard 
Y, Serruys PW, Reifart N. European experience with the retrograde approach for the recanalisation of coronary 
artery chronic total occlusions. A report on behalf of the euroCTO club. EuroIntervention 2008;4:84-92 
20. de Labriolle A, Bonello L, Roy P, Lemesle G, Steinberg DH, Xue Z, Kaneshige K, Suddath WO, Satler 
LF, Kent KM, Pichard AD, Lindsay J, Waksman R. Comparison of safety, efficacy, and outcome of successful 
versus unsuccessful percutaneous coronary intervention in "true" chronic total occlusions. Am J 
Cardiol 2008;1:1175-1178 
21. Jolicoeur EM, Sketch MJ, Wojdyla DM, Javaheri SP, Nosib S, Lokhnygina Y, Patel MR, Shaw LK, Tcheng JE. 
Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions. 
Catheter Cardiovasc Interv 2012;79:603-612 
22. Lee SW, Lee JY, Park DW, Kim YH, Yun SC, Kim WJ, Suh J, Cho YH, Lee NH, Kang SJ, Lee CW, Park 
SW, Park SJ. Long-term clinical outcomes of successful versus unsuccessful revascularization with 
drug-eluting stents for true chronic total occlusion. Catheter Cardiovasc Interv 2011;78:346-353.   
23. Valenti R, Migliorini A, Signorini U, Vergara R, Parodi G, Carrabba N, Cerisano G, Antoniucci D. Impact of 
complete revascularization with percutaneous coronary intervention on survival in patients with at least 
  
18 
one chronic total occlusion. Eur Heart J 2008;29:2336-2342 
24. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, Gannot S, Samuel M, Weisbrod 
M, Bierstone D, Sparkes JD, Wright GA, Strauss BH. Current perspectives on coronary chronic total 
occlusions: The Canadian multicenter chronic total occlusions registry. J Am Coll Cardiol 2012;59:991-997 
25. Aziz S, Stables RH, Grayson AD, Perry RA, Ramsdale DR. Percutaneous coronary intervention for chronic 
total occlusions: Improved survival for patients with successful revascularization compared to a failed 
procedure. Catheter Cardiovasc Interv 2007;70:15-  
26. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol 
G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG,Mavromatis K, Manoharan G, Verlee P, Frobert 
O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. 
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J 
Med 2012;367:991-1001 
27. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den 
Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous 
coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 
2009;360:961-72. 
28. Bansilal S, Farkouh ME, Hueb W, Ogdie M, Dangas G, Lansky AJ, Cohen DJ, Magnuson EA, Ramanathan 
K, Tanguay JF, Muratov V, Sleeper LA, Domanski M,Bertrand ME, Fuster V. The Future REvascularization 
Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: 
  
19 
clinical and angiographic profile at study entry. Am Heart J 2012;164:591-599. 
29. Safley DM, House JA, Marso SP, Grantham JA, Rutherford BD. Improvement in survival following successful 
percutaneous coronary intervention of coronary chronic total occlusions: Variability by target vessel. JACC 




Figure 1.  
Study flow chart.  
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CTO, chronic total occlusion. 
Figure 2. 
Cumulative incidences of (A) all-cause death and (B) cardiac death: the success PCI vs. failed PCI group. 
PCI, percutaneous coronary intervention; 
Figure 3. 
Cumulative incidences of (A) myocardial infarction, (B) stroke, (C) CABG and (D) any coronary revascularization: 
the success PCI vs. failed PCI group. 




Table 1. Baseline Characteristics: Successful versus Failed PCI for Chronic Total Occlusion  
 Variable 
Success Failure P value 
(N=1192) (N=332)  
(A) Clinical characteristics    
 Age (years)  66.9±10.8 66.2±10.7 0.32 
   Age >= 75* 324 (27%) 80 (24%) 0.26 
 Male* 926 (78%) 253 (76%) 0.57 
 BMI (kg/m
2
) 24.2±3.6 24.3±3.6 0.82 
   BMI < 25.0** 762 (64%) 205 (62%) 0.47 
 Acute myocardial infarction* 101 (8.5%) 63 (19%) <0.0001 
 Hypertension* 989 (83%) 290 (87%) 0.055 
 Diabetes mellitus 498 (42%) 141 (42%) 0.82 
   on insulin therapy* 114 (9.6%) 32 (9.6%) 0.97 
 Current smoker* 389 (33%) 118 (36%) 0.32 
 Heart failure** 258 (22%) 81 (24%) 0.29 
 Shock at presentation* 25 (2.1%) 19 (5.7%) 0.001 
 Multivessel coronary disease** 853 (72%) 277 (83%) <0.0001 
 Mitral regurgitation grade 3/4* 65 (7.1%) 31 (13%) 0.005 
 Ejection fraction (%) 55.4 ±13.4 54.3 ±14.6 0.23 
 Prior myocardial infarction* 381 (32%) 80 (24%) 0.006 
 Prior stroke* 178 (15%) 56 (17%) 0.39 
 Peripheral vascular disease* 93 (7.8%) 27 (8.1%) 0.84 
 eGFR < 30, not on dialysis** 45 (3.8%) 13 (3.9%) 0.91 
 Dialysis** 43 (3.6%) 27 (8.1%) 0.0005 
 Atrial fibrillation* 99 (8.3%) 26 (7.8%) 0.78 
 Anemia (hemoglobin < 11 g/dl)**  131 (11%) 40 (12%) 0.59 
 Platelet < 100*10
9
/L* 17 (1.4%) 4 (1.2%) 0.76 
 Chronic obstructive pulmonary disease* 35 (2.9%) 11 (3.3%) 0.72 
 Liver cirrhosis* 27 (2.3%) 8 (2.4%) 0.88 
 Malignancy* 80 (6.7%) 26 (7.8%) 0.48 
(B) Procedural characteristics    
 Number of target lesions 1.8±0.9 1.8±0.9 0.96 
 Number of target vessels 1.6±0.7 1.6±0.7 0.88 
 Number of CTO vessels 1.1±0.4 1.2±0.4 0.4 
 Number of target CTO vessels 1.0±0.2 1.0±0.1 0.053 
 Location of target CTO     
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   Left anterior descending 505 (42%) 121 (36%) 0.053 
   Proximal left anterior descending* 458 (38%) 111 (33%) 0.1 
   Left circumflex 346 (29%) 88 (27%) 0.37 
   Right 507 (43%) 176 (53%) 0.0007 
   Unprotected left main* 1 (0.1%) 0 0.6 
 Contrast media volume 211 (150-303) 207 (146-300) 0.26 
(C) Baseline medication    
 Antiplatelet therapy    
   Thienopyridine 1172 (98%) 303 (91%) <0.0001 
       Ticlopidine 1058 (91%) 279 (92%) 0.42 
       Clopidogrel 110 (9.4%) 24 (7.9%)  
   Aspirin 1181 (99%) 322 (97%) 0.004 
   Cilostazol* 140 (12%) 48 (14%) 0.18 
 Other medications    
   Statin** 633 (53%) 160 (48%) 0.11 
   Beta-blockers* 379 (32%) 124 (37%) 0.06 
   ACE-I / ARB** 678 (57%) 195 (59%) 0.55 
   Nitrates* 475 (40%) 155 (47%) 0.03 
   Calcium channel blockers* 488 (41%) 140 (42%) 0.69 
   Nicorandil* 303 (25%) 93 (28%) 0.34 
   Warfarin* 99 (8.3%) 28 (8.4%) 0.94 
   Proton pump inhibitors* 278 (23%) 71 (21%) 0.46  
   H2-blockers* 267 (22%) 86 (26%) 0.18 
Values are expressed as mean ± SD or median (inter-quartile range).  
BMI indicated body mass index; eGFR, estimated glomerular filtration rate; CTO, chronic total occlusion; ACE-I, 
angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers.  
* Potential independent variables selected for Cox proportional hazard models. 




Table 2. Procedural Complications and In-hospital Adverse Events   
 Variable 
Success Failure P value 
(N=1192) (N=332)  
Procedural Complications    
 Coronary dissection 12 (1.0%) 5 (1.5%) 0.44 
 Coronary perforation 7 (0.6%) 10 (3.0%) 0.0002 
 Cardiac tamponade 3 (0.3%) 2 (0.6%) 0.32 
 Pericardial drainage 0 1 (0.3%) 0.06 
    
In-hospital adverse events    
 Death 17 (1.4%) 10 (3.0%) 0.053 
 Myocardial infarction 10 (0.8%) 7 (2.1%) 0.053 
 Stroke 5 (0.4%) 2 (0.6%) 0.66 
 Coronary bypass 0 1 (0.3%) 0.06 







Table 3. Unadjusted and Adjusted Risk for Clinical Events     
 Success Failure Unadjusted P value Adjusted P value 
 Variable 
N of events /N of 
patients  
N of events /N of 
patients  
HR (95%CI)  HR (95%CI)  
 (Incidence) (Incidence)     




0.93 (0.64-1.37) 0.69 




0.71 (0.44-1.16) 0.16 




0.60 (0.33-1.13) 0.11 




0.81 (0.49-1.40) 0.45 




0.09 (0.06-0.15) <0.0001 
  Any coronary 
revascularization 




0.50 (0.41-0.60) <0.0001 
Cumulative incidence was estimated by the Kaplan-Meier method. 




Table 4. Subgroup Analysis for All-cause Death and Cardiac Death at 3 Years     
 Success Failure  P value   
 Variable 
N of events /N of 
patients  






 (Incidence) (Incidence)     
All-cause death       
Multivessel coronary disease 79/853 (10.8%)  30/277 (13.7%) 0.92 (0.62-1.40) 0.69   
Single vessel coronary disease 13/399 (4.6%)  5/55 (9.9%) 0.40 (0.15-1.23) 0.06   
       
History of heart failure 50/258 (22.1%)  16/81 (24.5%) 1.01 (0.60-1.84) 0.98   
No history of heart failure 42/934 (5.4%)  19/251 (9.5%) 0.63 (0.29-1.07) 0.07   
       
Left anterior descending 35/505 (8.3%)  14/121 (13.3%) 0.67 (0.38-1.28) 0.19   
Non-left anterior descending 57/687 (9.6%)  21/211 (13.0%) 0.83 (0.52-1.37) 0.45   
       
Diabetes mellitus 48/498 (11.4%)  14/141 (11.3%) 0.99 (0.57-1.82) 0.97   
Non-diabetes mellitus 44/694 (7.4%) 21/191 (14.5%) 0.62 (0.38-1.04) 0.06   
       
Cardiac death       
Multivessel coronary disease 40/853 (5.6%)  19/277 (8.1%) 0.76 (0.45-1.30) 0.3   
Single vessel coronary disease 6/399 (1.8%)  5/55 (9.9%) 0.20 (0.06-0.68) 0.01   
       
History of heart failure 35/258 (15.6%)  12/81 (17.6%) 0.94 (0.51-1.88) 0.86   
No history of heart failure 11/934 (1.5%)  12/251 (5.5%) 0.32 (0.16-0.68) 0.004   
       
Left anterior descending 15/505 (3.7%)  10/121 (9.2%) 0.43 (0.21-0.97) 0.04   
Non-left anterior descending 14/687 (5.1%)  14/211 (8.0%) 0.70 (0.39-1.33) 0.27   
       
Diabetes mellitus 26/498 (6.2%)  11/141 (8.4%) 0.71 (0.38-1.45) 0.33   













Patients without CTO 10596 patients
Successful CTO-PCI
1192 patients
Patients without treated CTO 967 patients
CREDO-Kyoto PCI/CABG Registry Cohort-2
15263 patients









(A) All-cause death (B) Cardiac death
Interval 0days 30days 1year 2years 3years
Success
Cumulative incidence 1.3% 4.5% 6.8% 9.0%
N of patients with event 15 53 77 92
N of patients at risk 1192 1175 1108 825 453
Failure
Cumulative incidence 2.4% 6.5% 8.0% 13.1%
N of patients with event 8 21 25 35
N of patietns at risk 332 315 289 222 128
Interval 0days 30days 1year 2years 3years
Success
Cumulative incidence 1.2% 2.8% 3.4% 4.5%
N of patients with event 14 33 39 46
N of patients at risk 1192 1175 1108 825 453
Failure
Cumulative incidence 2.4% 5.3% 6.4% 8.4%
N of patients with event 8 17 20 24
N of patients at risk 332 315 289 222 128





(A) Myocardial infarction (B) Stroke
Interval 0days 30days 1year 2years 3years
Success
Cumulative incidence 0.8% 1.8% 2.2% 3.2%
N of patients with event 10 21 25 30
N of patients at risk 1192 1166 1089 808 442
Failure
Cumulative incidence 2.2% 3.1% 4.3% 5.5%
N of patients with event 7 10 13 15









Interval 0days 30days 1year 2years 3years
Success
Cumulative incidence 1.2% 3.0% 4.1% 5.0%
N of patients with event 14 35 46 52
N of patients at risk 1192 1163 1085 803 439
Failure
Cumulative incidence 1.9% 5.1% 6.3% 6.3%
N of patients with event 6 16 19 19
N of patients at risk 332 310 278 209 121
(C) CABG (D) Any revascularization
Interval 0days 30days 1year 2years 3years
Success
Cumulative incidence 0.3% 1.6% 1.8% 1.8%
N of patients with event 3 18 20 20
N of patients at risk 1192 1172 1089 808 444
Failure
Cumulative incidence 8.5% 17.9% 19.0% 19.6%
N of patients with event 27 56 59 60
N of patients at risk 332 289 236 174 97
Interval 0days 30days 1year 2years 3years
Success
Cumulative incidence 1.5% 28.1% 33.1% 35.5%
N of patients with event 18 321 373 389
N of patients at risk 1192 1159 798 570 307
Failure
Cumulative incidence 15.1% 48.8% 54.2% 55.7%
N of patients with event 48 151 165 167
N of patients at risk 332 268 146 97 50
Log rank p<0.0001
Log rank p<0.0001





Supplemental Table 1. Unadjusted and Adjusted Analysis for All-cause Death  
 Unadjusted P value Adjusted P value 
 Variable HR (95%CI)  HR (95%CI)  
CTO Success 0.77 (0.53-1.13) 0.18 0.93 (0.64-1.37) 0.69 
Age >=75 2.55 (1.83-3.54) <0.0001   
Male 1.17 (0.79-1.81) 0.44   
BMI <25.0 2.85 (1.89-4.49) <0.0001 2.09 (1.37-3.33) 0.0005 
Acute myocardial infarction 2.29 (1.50-3.39) 0.0003   
Hypertension 1.02 (0.67-1.64) 0.92   
Diabetes mellitus on insulin therapy 2.03 (1.29-3.07) 0.003   
Current smorker 0.80 (0.55-1.14) 0.21   
Heare failure 3.79 (2.73-5.27) <0.0001 3.27 (2.32-4.59) <0.0001 
Shock at presentation 6.91 (4.08-11.03) <0.0001   
Multivessel coronary disease 2.32 (1.47-3.88) 0.0002 2.69 (1.69-4.52) <0.0001 
Mitral regurgitation grade 3/4 1.99 (1.10-3.33) 0.02   
Prior myocardial infarction 1.37 (0.97-1.91) 0.07   
Prior stroke 1.73 (1.15-2.52) 0.009   
Peripheral vascular disease 2.12 (1.30-3.29) 0.0037   
eGFR<30, not on dialysis 4.21 (2.54-6.88) <0.0001 2.92 (1.68-4.83) 0.0003 
Dialysis 5.39 (3.39-8.21) <0.0001 3.24 (1.92-5.31) <0.0001 
Atrial fibrillation 2.45 (1.54-3.73) 0.003   
Anemia (hemoglobin <11 g/dl) 4.61 (3.23-6.49) <0.0001 2.09 (1.39-3.10) 0.0005 
Platelet < 100*10
9
/L 2.71 (0.96-5.95) 0.06   
Chronic obstructive pulmonary disease 0.91 (0.28-2.14) 0.84   
Liver cirrhosis 0.91 (0.23-2.41) 0.87   
Malignancy 1.92 (1.11-3.09) 0.02   
Target of proximal LAD 1.20 (0.86-1.69) 0.29   
Target of unprotected LMCA 1.31 (0.40-3.10) 0.61   
Cirostazole use 0.95 (0.56-1.51) 0.83   
Statins use 0.43 (0.30-0.60) <0.0001 0.62 (0.42-0.89) 0.0092 
Beta-blockers use 0.90 (0.62-1.27) 0.55   
ACE-I/ARB use 0.66 (0.48-0.92) 0.01 0.62 (0.44-0.87) 0.0062 
Nitrate use 0.88 (0.63-1.23) 0.46   
Calcium chanel blockers use 0.87 (0.62-1.22) 0.43   
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Nicorandil use 0.97 (0.66-1.40) 0.87   
Warfarin use 1.33 (0.76-2.16) 0.3   
Proton pump inhibitors use 1.86 (1.30-2.3) 0.001   
H2-blockers use 0.92 (0.61-1.35) 0.67   
CTO indicated chronic total occlusion; BMI, body mass index; eGFR, estimated glomerular filtration rate; LAD, left 
anterior descending artery; LMCA, left main coronary artery; ACE-I, angiotensin converting enzyme inhibitors; ARB, 
angiotensin II receptor blockers. 
  
31 
Supplemental Figure 1 


































































Supplemental Figure 2 
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Log rank p<0.0001	 
Persistent Discontinuation of Thienopyridine 
Interval 0days 30days 1year 2years 3years 
Success 
Cumulative incidence 10% 40% 48% 52% 
N of patients with event 122 456 538 558 
N of patients at risk 1192 1042 653 402 175 
Failure	
Cumulative incidence 45% 66% 70% 71% 
N of patients with event 146 212 221 222 
N of patients at risk 332 176 95 54 27 
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(B) Persistent Discontinuation of Thienopyridine
           BMS only	


























Log rank p<0.0001	 
Persistent Discontinuation of Thienopyridine 
Interval 0days 30days 1year 2years 3years 
DES 
Cumulative incidence 2.8% 27% 37% 41% 
N of patients with event 26 234	 305	 325	
N of patients at risk 900 852 601 374 161 
BMS only	
Cumulative incidence 29% 79% 84% 84% 
N of patients with event 73 194 203 203 
N of patients at risk 256 177 45 25 14 
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Supplemental Appendix A: List of participating centers and investigators for the 
CREDO-Kyoto PCI/CABG Registry Cohort-2 
 
Cardiology 
Kyoto University Hospital: Takeshi Kimura 
Kishiwada City Hospital: Mitsuo Matsuda, Hirokazu Mitsuoka 
Tenri Hospital: Yoshihisa Nakagawa 
Hyogo Prefectural Amagasaki Hospital: Hisayoshi Fujiwara, Yoshiki Takatsu, Ryoji Taniguchi 
Kitano Hospital: Ryuji Nohara 
Koto Memorial Hospital: Tomoyuki Murakami, Teruki Takeda 
Kokura Memorial Hospital: Masakiyo Nobuyoshi, Masashi Iwabuchi 
Maizuru Kyosai Hospital: Ryozo Tatami 
Nara Hospital, Kinki University Faculty of Medicine: Manabu Shirotani 
Kobe City Medical Center General Hospital: Toru Kita, Yutaka Furukawa, Natsuhiko Ehara 
Nishi-Kobe Medical Center: Hiroshi Kato, Hiroshi Eizawa 
Kansai Denryoku Hospital: Katsuhisa Ishii 
Osaka Red Cross Hospital: Masaru Tanaka 
University of Fukui Hospital: Jong-Dae Lee, Akira Nakano 
Shizuoka City Shizuoka Hospital: Akinori Takizawa 
Hamamatsu Rosai Hospital: Masaaki Takahashi 
Shiga University of Medical Science Hospital: Minoru Horie, Hiroyuki Takashima 
Japanese Red Cross Wakayama Medical Center: Takashi Tamura 
Shimabara Hospital: Mamoru Takahashi 
Kagoshima University Medica and Dental Hospital: Chuwa Tei, Shuichi Hamasaki 
Shizuoka General Hospital: Hirofumi Kambara, Osamu Doi, Satoshi Kaburagi 
Kurashiki Central Hospital: Kazuaki Mitsudo, Kazushige Kadota 
Mitsubishi Kyoto Hospital: Shinji Miki, Tetsu Mizoguchi 
Kumamoto University Hospital: Hisao Ogawa, Seigo Sugiyama 
Shimada Municipal Hospital: Ryuichi Hattori, Takeshi Aoyama, Makoto Araki 
Juntendo University Shizuoka Hospital: Satoru Suwa 
 
Cardiovascular Surgery 
Kyoto University Hospital: Ryuzo Sakata, Tadashi Ikeda, Akira Marui 
Kishiwada City Hospital: Masahiko Onoe 
Tenri Hospital: Kazuo Yamanaka 
Hyogo Prefectural Amagasaki Hospital: Keiichi Fujiwara, Nobuhisa Ohno 
Kokura Memorial Hospital: Michiya Hanyu 
Maizuru Kyosai Hospital:  Tsutomu Matsushita 
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Nara Hospital, Kinki University Faculty of Medicine: Noboru Nishiwaki, Yuichi Yoshida 
Kobe City Medical Center General Hospital: Yukikatsu Okada, Michihiro Nasu 
Osaka Red Cross Hospital: Shogo Nakayama 
University of Fukui Hospital: Kuniyoshi Tanaka, Takaaki Koshiji, Koichi Morioka 
Shizuoka City Shizuoka Hospital: Mitsuomi Shimamoto, Fumio Yamazaki 
Hamamatsu Rosai Hospital: Junichiro Nishizawa 
Japanese Red Cross Wakayama Medical Center: Masaki Aota 
Shimabara Hospital: Takafumi Tabata 
Kagoshima University Medica and Dental Hospital: Yutaka Imoto, Hiroyuki Yamamoto 
Shizuoka General Hospital: Katsuhiko Matsuda, Masafumi Nara 
Kurashiki Central Hospital: Tatsuhiko Komiya 
Mitsubishi Kyoto Hospital: Hiroyuki Nakajima 
Kumamoto University Hospital: Michio Kawasuji, Syuji Moriyama 
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Yuki Sato, Chikako Hibi, Hitomi Sasae, Emi Takinami, Yuriko Uchida, Yuko Yamamoto, Satoko Nishida, Mai 
Yoshimoto, Sachiko Maeda, Izumi Miki, Saeko Minematsu.  
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